Welcome to our dedicated page for Optimizerx news (Ticker: OPRX), a resource for investors and traders seeking the latest updates and insights on Optimizerx stock.
OptimizeRx Corp (NASDAQ: OPRX) provides a dedicated news hub for tracking developments in healthcare technology and digital patient engagement solutions. This page aggregates official announcements, financial disclosures, and strategic updates from the leader in EHR-integrated pharma messaging.
Investors and industry professionals will find curated coverage of earnings reports, technology partnerships, product launches, and regulatory milestones. The resource serves as a centralized source for understanding OPRX's role in connecting pharmaceutical companies with healthcare providers through cloud-based communication platforms.
Key content categories include financial results, strategic alliances with EHR providers, technology innovations in digital health messaging, and industry recognition of platform advancements. All materials maintain factual accuracy and timeliness required for informed decision-making.
Bookmark this page for streamlined access to OptimizeRx's evolving position in medication adherence solutions and AI-driven healthcare communications. Regular updates ensure stakeholders stay informed about developments impacting the digital pharma marketing landscape.
OptimizeRx Corp (Nasdaq: OPRX) will hold a conference call on May 10, 2023, at 4:30 p.m. Eastern Time to discuss its first-quarter results for the period ending March 31, 2023. The financial results will be released prior to the call. Interested parties can join via a toll-free number at 1-888-886-7786 or internationally at 1-416-764-8658, using conference ID 54210852. The call will also be accessible through a webcast. A replay will be available for 12 months on OptimizeRx’s investor website. OptimizeRx focuses on providing technology solutions that improve patient engagement and ensure adherence to therapies.
OptimizeRx (Nasdaq: OPRX) has announced a share repurchase program, allowing for the buyback of up to $15 million of its common stock. The Board of Directors unanimously approved this decision, reflecting the company's solid working capital and belief that its shares are undervalued. CEO Will Febbo highlighted the long-term confidence in OptimizeRx's business, emphasizing the scalability offered by its extensive point-of-care network, which connects over 60% of U.S. healthcare providers.
OptimizeRx Corp (Nasdaq: OPRX) has entered a multi-million-dollar, three-year agreement with a leading Hub services company to enhance patient services using OptimizeRx’s technology solutions. This partnership aims to streamline access to medication through digitization, addressing eligibility and affordability for pharma-sponsored programs.
The collaboration is set to improve efficiency in navigating patient care management, reducing the administrative burden on healthcare providers, who currently spend significant time assisting patients. Given the rising demand for specialty therapies, this development positions OptimizeRx favorably in the growing market for health technology solutions.
OptimizeRx Corp. (Nasdaq: OPRX) reported Q4 2022 revenue of $19.7 million, a 3% decrease year-over-year but a 30% increase quarter-over-quarter. Gross profit rose 1% to $12.5 million, with gross margins improving from 61% to 63%. The company generated $10.7 million in cash flow from operations for 2022 and repurchased 1.2 million shares at an average price of $16.49. For 2023, OptimizeRx anticipates at least 10% revenue growth year-over-year while maintaining gross margins between 58% and 62%.
OptimizeRx Corp. (Nasdaq: OPRX) announced a conference call on March 8, 2023, at 4:30 p.m. Eastern Time to discuss its fourth-quarter and fiscal year results for 2022. The financial results will be released prior to the call, which will include a Q&A session with management. OptimizeRx connects over 60% of U.S. healthcare providers and patients through its advanced health technology solutions, enhancing medication access and adherence. Interested parties can join the call via a toll-free number or webcast, and a replay will be available on the Investors section of the company's website for 12 months.
OptimizeRx Corp (Nasdaq: OPRX) announced that Karina Castagna, its senior VP of access and adherence, is included in MM+M’s 40 Under 40 List, recognizing her contributions to healthcare marketing. Castagna has enhanced physician access to digital solutions since joining OptimizeRx in 2021, effectively breaking down prescribing barriers. Her efforts led to a remarkable 300% increase in prescriptions and a 60% hike in prior authorization submissions for a specialty diabetes medication at one client Hub. The recognition ceremony will take place on February 16, 2023, at The Edison Ballroom in New York City.
